Coronary Artery Disease Peripheral Arterial Disease Technology 
DAIC
JUNE 18, 2024
Elixir Medical has announced the company’s novel bioadaptive implant, DynamX Sirolimus-Eluting Coronary Bioadaptor System, has been granted Breakthrough Device Designation by the U.S. After implantation, the locked phase establishes the maximum flow lumen and restores blood flow to treat symptoms of coronary artery disease (CAD).
DAIC
MARCH 20, 2024
CLTI is the most severe form of peripheral arterial disease (PAD), estimated to affect 11% of the 200 million people suffering from PAD globally. degradation of magnesium observed 12 months after implantation in coronary arteries.4 2,3 It has shown 99.6%
DAIC
MARCH 27, 2024
The company reports this broadens the use of the novel bioadaptor platform technology beyond the treatment of coronary artery disease. The DynamX Bioadaptor platform is a medical technology designed to establish the new standard of care for vascular interventions, according to a written statement on the designation.
DAIC
MAY 8, 2024
1 Atherosclerosis is a systemic disease that affects multiple vascular regions and is particularly severe in PAD patients, where up to 80 percent suffer from concurrent coronary artery disease (CAD), historically linked with a mortality rate exceeding 50 percent within five years. Journal of Vascular Surgery, Mar.
DAIC
MAY 31, 2024
Joaquin Duato , Chairman and Chief Executive Officer of Johnson & Johnson, said, “Through Innovative Medicine and MedTech, Johnson & Johnson is transforming the trajectory of cardiovascular disease, one of the leading causes of death globally.
DAIC
APRIL 5, 2024
With the addition of Shockwave, Johnson & Johnson will expand its MedTech cardiovascular portfolio into two of the highest-growth, innovation-oriented segments of cardiovascular intervention – coronary artery disease (CAD) and peripheral artery disease (PAD).
Expert insights. Personalized for you.
105 
Let's personalize your content